Literature DB >> 32380543

Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates.

Marie-Laure Arotcarena1,2, Sandra Dovero1,2, Alice Prigent3,4,5, Mathieu Bourdenx1,2, Sandrine Camus1,2, Gregory Porras1,2, Marie-Laure Thiolat1,2, Maddalena Tasselli3,4,5, Philippe Aubert3,4,5, Niels Kruse6,7, Brit Mollenhauer6,7, Ines Trigo Damas8,9,10, Cristina Estrada11,12, Nuria Garcia-Carrillo13, Nishant N Vaikath14, Omar M A El-Agnaf14, Maria Trinidad Herrero11,12, Miquel Vila15,16,17, Jose A Obeso8,9,10, Pascal Derkinderen3,4,5, Benjamin Dehay1,2, Erwan Bezard1,2.   

Abstract

In Parkinson's disease, synucleinopathy is hypothesized to spread from the enteric nervous system, via the vagus nerve, to the CNS. Here, we compare, in baboon monkeys, the pathological consequences of either intrastriatal or enteric injection of α-synuclein-containing Lewy body extracts from patients with Parkinson's disease. This study shows that patient-derived α-synuclein aggregates are able to induce nigrostriatal lesions and enteric nervous system pathology after either enteric or striatal injection in a non-human primate model. This finding suggests that the progression of α-synuclein pathology might be either caudo-rostral or rostro-caudal, varying between patients and disease subtypes. In addition, we report that α-synuclein pathological lesions were not found in the vagal nerve in our experimental setting. This study does not support the hypothesis of a transmission of α-synuclein pathology through the vagus nerve and the dorsal motor nucleus of the vagus. Instead, our results suggest a possible systemic mechanism in which the general circulation would act as a route for long-distance bidirectional transmission of endogenous α-synuclein between the enteric and the central nervous systems. Taken together, our study provides invaluable primate data exploring the role of the gut-brain axis in the initiation and propagation of Parkinson's disease pathology and should open the door to the development and testing of new therapeutic approaches aimed at interfering with the development of sporadic Parkinson's disease.
© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Parkinson’s disease; gut; monkey; neurodegeneration; α-synuclein

Mesh:

Substances:

Year:  2020        PMID: 32380543     DOI: 10.1093/brain/awaa096

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  30 in total

1.  Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  CNS Drugs       Date:  2022-02-25       Impact factor: 5.749

Review 2.  The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.

Authors:  Ai Huey Tan; Shen Yang Lim; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2022-06-24       Impact factor: 44.711

Review 3.  Prodromal Parkinson disease subtypes - key to understanding heterogeneity.

Authors:  Daniela Berg; Per Borghammer; Seyed-Mohammad Fereshtehnejad; Sebastian Heinzel; Jacob Horsager; Eva Schaeffer; Ronald B Postuma
Journal:  Nat Rev Neurol       Date:  2021-04-20       Impact factor: 42.937

Review 4.  Role of Microgliosis and NLRP3 Inflammasome in Parkinson's Disease Pathogenesis and Therapy.

Authors:  Fillipe M de Araújo; Lorena Cuenca-Bermejo; Emiliano Fernández-Villalba; Silvia L Costa; Victor Diogenes A Silva; Maria Trinidad Herrero
Journal:  Cell Mol Neurobiol       Date:  2021-01-02       Impact factor: 5.046

Review 5.  Exosomes in Parkinson disease.

Authors:  Jennifer R Pinnell; Mei Cui; Kim Tieu
Journal:  J Neurochem       Date:  2021-01-22       Impact factor: 5.372

Review 6.  Brain regions susceptible to alpha-synuclein spreading.

Authors:  Yu-Jie Guo; Huan Xiong; Kang Chen; Jin-Jun Zou; Peng Lei
Journal:  Mol Psychiatry       Date:  2021-09-24       Impact factor: 15.992

7.  Staging Parkinson's Disease Combining Motor and Nonmotor Symptoms Correlates with Disability and Quality of Life.

Authors:  D Santos García; T De Deus Fonticoba; J M Paz González; C Cores Bartolomé; L Valdés Aymerich; J G Muñoz Enríquez; E Suárez; S Jesús; M Aguilar; P Pastor; L L Planellas; M Cosgaya; J García Caldentey; N Caballol; I Legarda; J Hernández Vara; I Cabo; L López Manzanares; I González Aramburu; M A Ávila Rivera; M J Catalán; V Nogueira; V Puente; J M García Moreno; C Borrué; B Solano Vila; M Álvarez Sauco; L Vela; S Escalante; E Cubo; F Carrillo Padilla; J C Martínez Castrillo; P Sánchez Alonso; M G Alonso Losada; N López Ariztegui; I Gastón; J Kulisevsky; M Blázquez Estrada; M Seijo; J Rúiz Martínez; C Valero; M Kurtis; O de Fábregues; J González Ardura; C Ordás; L López Díaz; P Mir; P Martinez-Martin
Journal:  Parkinsons Dis       Date:  2021-05-13

Review 8.  An Update on Medical and Surgical Treatments of Parkinson's Disease.

Authors:  Dipali Nemade; Thyagarajan Subramanian; Vikram Shivkumar
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

Review 9.  A New Rise of Non-Human Primate Models of Synucleinopathies.

Authors:  Margaux Teil; Marie-Laure Arotcarena; Benjamin Dehay
Journal:  Biomedicines       Date:  2021-03-09

Review 10.  Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease.

Authors:  Luis M A Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A Lashuel; David Sulzer; Kostas Vekrellis; Glenda M Halliday; Julianna J Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F Outeiro
Journal:  NPJ Parkinsons Dis       Date:  2021-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.